HONG KONG – Brii Biosciences has entered into two significant partnerships to expand its pipeline. The first is a license and collaboration agreement with VBI Vaccines Ltd. and Vir Biotechnology Inc. focused on hepatitis B virus (HBV) infection. Brii Bio licensed greater China rights, which includes the Chinese mainland, Hong Kong, Macau and Taiwan, for a recombinant protein-based immunotherapeutic (VBI-2601) from VBI Vaccines in a deal that could be worth up to $129 million plus royalties. The second is a China-based exclusive research agreement with Wuxi Biologics Co. Ltd. and Tsinghua University Institute for Immunology to discover and develop bispecific antibodies to treat infectious diseases and other immunologic disorders.